A combination strategy of inotuzumab ozogamicin (InO) and BCL-2 family inhibitors prevents the emergence of PGP+ ino-resistant MRD in B-cell acute lymphoblastic leukemia
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Anna Akaogi, Kenichi Ishiyama, Toshio Kitawaki, Hiroshi Arima, Tadahiko Matsumoto, Ernesto Diaz-Flores, Mignon Loh, Akifumi Takaori-Kondo
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108756963
Cites:
Cited by:
Related to: